Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
Status:
Recruiting
Trial end date:
2025-03-10
Target enrollment:
Participant gender:
Summary
The study is an open-label Phase 1 study of the combination of relacorilant with enzalutamide
in patients with metastatic castration resistant prostate cancer (mCRPC).
Phase:
Phase 1
Details
Lead Sponsor:
University of Chicago
Collaborators:
Corcept Therapeutics National Cancer Institute (NCI)